SCHEMBL3016480

SCHEMBL3016480

COc1cc(-c2oc3ccc(CCC(=O)N4CCNCC4)cc3c2SC)ccc1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 6/20 0.41
CSNK2B P67870 6/20 0.41
CSNK2A1 P68400 6/20 0.41
TMEM97 Q5BJF2 2/20 0.39
KCNH2 Q12809 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
ALOX5 P09917 1/20 0.38
OR51E2 Q9H255 1/20 0.38
ROCK2 O75116 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CYP3A4 P08684 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017931 0.92 CSNK2A2 (0.43) CSNK2A2CSNK2BCSNK2A1TMEM97KCNH2
SCHEMBL3005882 0.92 CSNK2A2 (0.43) CSNK2A2CSNK2BCSNK2A1ALOX5OR51E2
SCHEMBL3000646 0.92 CSNK2A2 (0.42) CSNK2A2CSNK2BCSNK2A1ALOX5OR51E2
SCHEMBL3009750 0.91 FKBP1A (0.47) CSNK2A2CSNK2BCSNK2A1TMEM97KCNH2
SCHEMBL3010624 0.86 ACHE (0.47) KMT2AALDH1A1MAPTGAA
SCHEMBL3007555 0.85 KMT2A (0.44) TLR9TLR8TLR7KMT2AMEN1
SCHEMBL3013194 0.85 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL3006035 0.84 CSNK2A2 (0.43) CSNK2A2CSNK2BCSNK2A1KMT2AMEN1
SCHEMBL3002198 0.84 KMT2A (0.43) TLR9TLR8TLR7KMT2AMEN1
SCHEMBL3008063 0.84 CSNK2A2 (0.48) CSNK2A2CSNK2BCSNK2A1ALOX5OR51E2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069321-B1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF MEDIFRON DBT CO LTD (KR) 2016-04-13 EP claimed
US-8580848-B2 Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-11-12 US claimed
US-20120245165-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DAEWOONG PHARMACEUTICAL CO., LTD (KR) 2012-09-27 US claimed
US-20100197685-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DIGITAL BIOTECH CO., LTD (KR) 2010-08-05 US claimed
EP-2069321-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF Digital Biotech Co., Ltd. (KR) 2009-06-17 EP claimed
WO-2008041826-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DIGITAL BIOTECH CO., LTD (KR) 2008-04-10 WO claimed
EP-2069321-B1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF MEDIFRON DBT CO LTD (KR) 2016-04-13 EP disclosed
US-8580848-B2 Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-11-12 US disclosed
US-8507553-B2 Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-08-13 US disclosed
US-8455542-B2 Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2013-06-04 US disclosed
US-20120259006-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DAEWOONG PHARMACEUTICAL CO., LTD (KR) 2012-10-11 US disclosed
US-20120245225-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DAEWOONG PHARMACEUTICAL CO., LTD (KR) 2012-09-27 US disclosed
US-20120245165-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DAEWOONG PHARMACEUTICAL CO., LTD (KR) 2012-09-27 US disclosed
US-8263649-B2 Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof MEDIFRON DBT CO., LTD. (KR) 2012-09-11 US disclosed
US-20100197685-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DIGITAL BIOTECH CO., LTD (KR) 2010-08-05 US disclosed
EP-2069321-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF Digital Biotech Co., Ltd. (KR) 2009-06-17 EP disclosed
WO-2008041826-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF DIGITAL BIOTECH CO., LTD (KR) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197685-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF APP, BACE1, PSEN1 CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885
US-20120259006-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF APP, BACE1, PSEN1 CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885
US-20120245165-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF APP, BACE1, PSEN1 CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885
US-20120245225-A1 NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF APP, BACE1, PSEN1 CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.